BACKGROUND: Although heparin is used to anticoagulate the extracorporeal circuit for most patients on maintenance hemodialysis (HD), some patients undergo heparin-free HD. We describe the determinants of heparin-free HD and its association with adverse outcomes using data from a national dialysis provider merged with Medicare claims. METHODS: We identified patients aged ≥67 years with no recent history of warfarin use who initiated maintenance HD from 2007 to 2008. We applied the Cox regression to a propensity score-matched cohort to estimate the hazards of all-cause mortality, bleeding (gastrointestinal hemorrhage, hemorrhagic stroke, other hemorrhage), atherothrombosis (ischemic stroke, myocardial infarction) and venous thromboembolism (VTE) (deep vein thrombosis, pulmonary embolism). RESULTS: Among 12 468 patients, 836 (6.7%) were dialyzed heparin-free. In multivariable-adjusted analyses, a history of gastrointestinal bleeding, hemorrhagic stroke and lower hemoglobin and platelet counts were associated with higher odds of heparin-free HD. Heparin-free HD use also varied as much as 4-fold by facility region. We found no significant association of heparin-free HD with all-cause mortality [hazard ratio (HR) 1.08; 95% confidence interval (CI): 0.94-1.26], bleeding (HR 1.15; 95% CI: 0.83-1.60), atherothrombosis (HR 1.09, 95% CI: 0.90-1.31) or VTE (HR 1.23, 95% CI: 0.93-1.64) compared with HD with heparin. CONCLUSIONS: Patient markers of increased risk of bleeding and facility region associated with heparin-free HD use. Despite the potential benefits of avoiding heparin use, heparin-free HD was not significantly associated with decreased hazards of death, bleeding or thrombosis, suggesting that it may be no safer than HD with heparin.
BACKGROUND: Although heparin is used to anticoagulate the extracorporeal circuit for most patients on maintenance hemodialysis (HD), some patients undergo heparin-free HD. We describe the determinants of heparin-free HD and its association with adverse outcomes using data from a national dialysis provider merged with Medicare claims. METHODS: We identified patients aged ≥67 years with no recent history of warfarin use who initiated maintenance HD from 2007 to 2008. We applied the Cox regression to a propensity score-matched cohort to estimate the hazards of all-cause mortality, bleeding (gastrointestinal hemorrhage, hemorrhagic stroke, other hemorrhage), atherothrombosis (ischemic stroke, myocardial infarction) and venous thromboembolism (VTE) (deep vein thrombosis, pulmonary embolism). RESULTS: Among 12 468 patients, 836 (6.7%) were dialyzed heparin-free. In multivariable-adjusted analyses, a history of gastrointestinal bleeding, hemorrhagic stroke and lower hemoglobin and platelet counts were associated with higher odds of heparin-free HD. Heparin-free HD use also varied as much as 4-fold by facility region. We found no significant association of heparin-free HD with all-cause mortality [hazard ratio (HR) 1.08; 95% confidence interval (CI): 0.94-1.26], bleeding (HR 1.15; 95% CI: 0.83-1.60), atherothrombosis (HR 1.09, 95% CI: 0.90-1.31) or VTE (HR 1.23, 95% CI: 0.93-1.64) compared with HD with heparin. CONCLUSIONS:Patient markers of increased risk of bleeding and facility region associated with heparin-free HD use. Despite the potential benefits of avoiding heparin use, heparin-free HD was not significantly associated with decreased hazards of death, bleeding or thrombosis, suggesting that it may be no safer than HD with heparin.
Authors: S T Normand; M B Landrum; E Guadagnoli; J Z Ayanian; T J Ryan; P D Cleary; B J McNeil Journal: J Clin Epidemiol Date: 2001-04 Impact factor: 6.437
Authors: Donal N Reddan; Diane L Frankenfield; Preston S Klassen; Joseph A Coladonato; Lynda Szczech; Curtis A Johnson; Anatole Besarab; Michael Rocco; William McClellan; Jay Wish; William F Owen Journal: Nephrol Dial Transplant Date: 2003-01 Impact factor: 5.992
Authors: Donal Reddan; Preston Klassen; Diane L Frankenfield; Lynda Szczech; Steve Schwab; Joseph Coladonato; Michael Rocco; Edmund G Lowrie; William F Owen Journal: J Am Soc Nephrol Date: 2002-08 Impact factor: 10.121
Authors: Haimanot Wasse; Daniel L Gillen; Adrianne M Ball; Bryan R Kestenbaum; Stephen L Seliger; Donald Sherrard; Catherine O Stehman-Breen Journal: Kidney Int Date: 2003-10 Impact factor: 10.612
Authors: Jenny I Shen; Anjali B Saxena; Maria E Montez-Rath; Lynn Leng; Tara I Chang; Wolfgang C Winkelmayer Journal: J Nephrol Date: 2016-08-02 Impact factor: 3.902
Authors: Jenny I Shen; Maria E Montez-Rath; Aya A Mitani; Kevin F Erickson; Wolfgang C Winkelmayer Journal: Pharmacoepidemiol Drug Saf Date: 2014-02-18 Impact factor: 2.890
Authors: Daniel C Leslie; Anna Waterhouse; Julia B Berthet; Thomas M Valentin; Alexander L Watters; Abhishek Jain; Philseok Kim; Benjamin D Hatton; Arthur Nedder; Kathryn Donovan; Elana H Super; Caitlin Howell; Christopher P Johnson; Thy L Vu; Dana E Bolgen; Sami Rifai; Anne R Hansen; Michael Aizenberg; Michael Super; Joanna Aizenberg; Donald E Ingber Journal: Nat Biotechnol Date: 2014-10-12 Impact factor: 54.908
Authors: Xiaohui Mou; Hongbo Zhang; Hua Qiu; Wentai Zhang; Ying Wang; Kaiqin Xiong; Nan Huang; Hélder A Santos; Zhilu Yang Journal: Research (Wash D C) Date: 2022-04-14
Authors: Sami Safadi; Robert C Albright; John J Dillon; Amy W Williams; Fares Alahdab; Julie K Brown; Amanda L Severson; Walter K Kremers; Mary Ann Ryan; Marie C Hogan Journal: Kidney Int Rep Date: 2017-03-16